Medicus Pharma Sharpens SkinJect Phase 2 Narrative, Pivots to 200µg Dose for Registrational Path

Medicus Pharma Ltd ( (MDCX) ) has issued an update.

Medicus Pharma clarified the interpretation of topline Phase 2 results for its SkinJect SKNJCT-003 study in nodular basal cell carcinoma, emphasizing that the drug-containing microneedle arms, not the device-only arm, drive the program’s therapeutic and regulatory value. The company highlighted that the 200µg doxorubicin microneedle cohort showed the strongest and improving activity by Day 57, providing decision-grade evidence to advance SkinJect toward an End-of-Phase 2 meeting, a registrational study focused on the 200µg dose, and potential strategic partnerships.

Management stated that the forthcoming Clinical Study Report will center on the 100µg and 200µg active treatment cohorts, detailing clinical and histological efficacy and dose response, while treating the device-only arm as supportive, non-pivotal data. This positioning is intended to remove confusion from the earlier topline release, sharpen the regulatory narrative, and reinforce SkinJect’s standing as a drug-device combination therapy with a non-surgical value proposition in non-melanoma skin cancer care.

The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.

The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech and life sciences company developing novel, potentially disruptive therapeutic assets. Its lead program, SkinJect, is an investigational doxorubicin-containing microneedle array designed as a non-surgical treatment for nodular basal cell carcinoma, targeting patients who seek non-invasive options or have limited access to skin surgery.

Average Trading Volume: 3,822,891

Technical Sentiment Signal: Sell

Current Market Cap: $18.07M

Find detailed analytics on MDCX stock on TipRanks’ Stock Analysis page.